|
1
|
Wang W, Xue Y, Zhou S, Kuo A, Cairns BR
and Crabtree GR: Diversity and specialization of mammalian SWI/SNF
complexes. Genes Dev. 10:2117–2130. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wilson BG and Roberts CW: SWI/SNF
nucleosome remodellers and cancer. Nat Rev Cancer. 11:481–492.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu JN and Roberts CW: ARID1A mutations in
cancer: Another epigenetic tumour suppressor? Cancer Discovery.
3:35–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jones S, Wang TL, Shih Ie M, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guan B, Gao M, Wu CH, Wang TL and Shih Ie
M: Functional analysis of in-frame indel ARID1A mutations reveals
new regulatory mechanisms of its tumour suppressor functions.
Neoplasia. 14:986–993. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang K, Kan J, Yuen ST, Shi ST, Chu KM,
Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing
identifies frequent mutation of ARID1A in molecular subtypes of
gastric cancer. Nat Genet. 43:1219–1223. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang SC, Ng KF, Chang IY, Chang CJ, Chao
YC, Chang SC, Chen MC, Yeh TS and Chen TC: The clinicopathological
significance of SWI/SNF alterations in gastric cancer is associated
with the molecular subtypes. PLoS One. 16:e02453562021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abe H, Maeda D, Hino R, Otake Y, Isogai M,
Ushiku AS, Matsusaka K, Kunita A, Ushiku T, Uozaki H, et al: ARID1A
expression loss in gastric cancer: Pathway-dependent roles with and
without Epstein-Barr virus infection and microsatellite
instability. Virchows Arch. 461:367–377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Drage MG, Tippayawong M, Agoston AT, Zheng
Y, Bueno R, Hornick JL, Odze RD and Srivastava A: Morphological
features and prognostic significance of ARID1A-deficient esophageal
adenocarcinomas. Arch Pathol Lab Med. 141:970–977. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schallenberg S, Bork J, Essakly A, Alakus
H, Buettner R, Hillmer AM, Bruns C, Schroeder W, Zander T, Loeser
H, et al: Loss of the SWI/SNF-ATPase subunit members SMARCF1
(ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in
oesophageal adenocarcinoma. BMC Cancer. 20:122020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC,
Shamanna RA, Bellani MA, Gaillard S, Ayhan A, Viswanathan A,
Seidman MM, et al: Loss of ARID1A in Tumor cells renders selective
vulnerability to combined ionizing radiation and PARP inhibitor
therapy. Clin Cancer Res. 25:5584–5594. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge
Z, Nagel ZD, Zou J, Wang C, Kapoor P, et al: ARID1A deficiency
promotes mutability and potentiates therapeutic antitumor immunity
unleashed by immune checkpoint blockade. Nat Med. 24:556–562. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hölscher AH, Schneider PM, Gutschow C and
Schröder W: Laparoscopic ischemic conditioning of the stomach for
esophageal replacement. Ann Surg. 245:241–246. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schneider PM, Metzger R, Schaefer H,
Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E,
Bollschweiler E, Baldus SE, Dienes HP, et al: Response evaluation
by endoscopy, rebiopsy, and endoscopic ultrasound does not
accurately predict histopathologic regression after neoadjuvant
chemoradiation for esophageal cancer. Ann Surg. 248:902–908. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simon R, Mirlacher M and Sauter G: Tissue
microarrays. Biotechniques. 36:98–105. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Helbig D, Ihle MA, Pütz K, Tantcheva-Poor
I, Mauch C, Büttner R and Quaas A: Oncogene and therapeutic target
analyses in atypical fibroxanthomas and pleomorphic dermal
sarcomas. Oncotarget. 7:21763–21774. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agaimy A, Daum O, Märkl B, Lichtmannegger
I, Michal M and Hartmann A: SWI/SNF Complex-deficient
Undifferentiated/Rhabdoid carcinomas of the gastrointestinal tract:
A Series of 13 cases highlighting mutually exclusive loss of
SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and
SMARCA2. Am J Surg Pathol. 40:544–553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Quaas A, Rehkaemper J, Rueschoff J, Pamuk
A, Zander T, Hillmer A, Siemanowski J, Wittig J, Buettner R, Plum
P, et al: Occurrence of high microsatellite-instability/mismatch
repair deficiency in nearly 2,000 human adenocarcinomas of the
gastrointestinal tract, pancreas, and bile ducts: A study from a
Large German comprehensive cancer Center. Front Oncol.
11:5694752021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Quaas A, Heydt C, Gebauer F, Alakus H,
Loeser H, Buettner R, Hillmer A, Bruns C, Merkelbach-Bruse S,
Zander T, et al: Genomic characterization of TP53-Wild-type
esophageal carcinoma. Transl Oncol. 12:154–161. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grossman RL, Heath AP, Ferretti V, Varmus
HE, Lowy DR, Kibbe WA and Staudt LM: Toward a shared vision for
cancer genomic data. N Engl J Med. 375:1109–1112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bonneville R, Krook MA, Kautto EA, Miya J,
Wing MR, Chen HZ, Reeser JW, Yu L and Roychowdhury S: Landscape of
microsatellite instability across 39 cancer types. JCO Precis
Oncol. 2017: PO.17.00073. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hewitt LC, Inam IZ, Saito Y, Yoshikawa T,
Quaas A, Hoelscher A, Bollschweiler E, Fazzi GE, Melotte V, Langley
RE, et al: Epstein-Barr virus and mismatch repair deficiency status
differ between oesophageal and gastric cancer: A large multi-centre
study. Eur J Cancer. 94:104–114. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Falkenback D, Johansson J, Halvarsson B
and Nilbert M: Defective mismatch-repair as a minor tumorigenic
pathway in Barrett esophagus-associated adenocarcinoma. Cancer
Genet Cytogenet. 157:82–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Frankell AM, Jammula S, Li X, Contino G,
Killcoyne S, Abbas S, Perner J, Bower L, Devonshire G, Ococks E, et
al: The landscape of selection in 551 esophageal adenocarcinomas
defines genomic biomarkers for the clinic. Nat Genet. 51:506–516.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dulak AM, Stojanov P, Peng S, Lawrence MS,
Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, et
al: Exome and whole-genome sequencing of esophageal adenocarcinoma
identifies recurrent driver events and mutational complexity. Nat
Genet. 45:478–486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chong IY, Cunningham D, Barber LJ,
Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S,
Garcia-Murillas I, et al: The genomic landscape of oesophagogastric
junctional adenocarcinoma. J Pathol. 231:301–310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Allo G, Bernardini MQ, Wu RC, Shih Ie M,
Kalloger S, Pollett A, Gilks CB and Clarke BA: ARID1A loss
correlates with mismatch repair deficiency and intact p53
expression in high-grade endometrial carcinomas. Modern Pathol.
27:255–261. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guan B, Wang TL and Shih Ie M: ARID1A, a
factor that promotes formation of SWI/SNF-mediated chromatin
remodeling, is a tumour suppressor in gynecologic cancers. Cancer
Res. 71:6718–6727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bosse T, ter Haar NT, Seeber LM, v Diest
PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H and Smit
VT: Loss of ARID1A expression and its relationship with PI3K-Akt
pathway alterations, TP53 and microsatellite instability in
endometrial cancer. Mod Pathol. 26:1525–1535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grabsch H, Sivakumar S, Gray S, Gabbert HE
and Müller W: HER2 expression in gastric cancer: Rare,
heterogeneous and of no prognostic value-conclusions from 924 cases
of two independent series. Cell Oncol. 32:57–65. 2010.PubMed/NCBI
|
|
33
|
Thuss-Patience PC, Shah MA, Ohtsu A, Van
Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G,
Shitara K, et al: Trastuzumab emtansine versus taxane use for
previously treated HER2-positive locally advanced or metastatic
gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An
international randomised, open-label, adaptive, phase 2/3 study.
Lancet Oncol. 18:640–653. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Knutson SK, Warholic NM, Wigle TJ, Klaus
CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP,
Copeland RA, et al: Durable tumour regression in genetically
altered malignant rhabdoid tumors by inhibition of
methyltransferase EZH2. Proc Natl Acad Sci USA. 110:7922–7927.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bitler BG, Aird KM, Garipov A, Li H,
Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih Ie M,
Conejo-Garcia JR, et al: Synthetic lethality by targeting EZH2
methyltransferase activity in ARID1A-mutated cancers. Nat Med.
21:231–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen J, Peng Y, Wei L, Zhang W, Yang L,
Lan L, Kapoor P, Ju Z, Mo Q, Shih Ie M, et al: ARID1A deficiency
impairs the DNA damage checkpoint and sensitizes cells to PARP
inhibitors. Cancer Discovery. 5:752–767. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Santo L, Hideshima T, Kung AL, Tseng JC,
Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et
al: Preclinical activity, pharmacodynamic, and pharmacokinetic
properties of a selective HDAC6 inhibitor, ACY-1215, in combination
with bortezomib in multiple myeloma. Blood. 119:2579–2589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Samartzis EP, Gutsche K, Dedes KJ, Fink D,
Stucki M and Imesch P: Loss of ARID1A expression sensitizes cancer
cells to PI3K- and AKT-inhibition. Oncotarget. 5:5295–5303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
St Pierre R and Kadoch C: Mammalian
SWI/SNF complexes in cancer: Emerging therapeutic opportunities.
Curr Opin Genet Dev. 42:56–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy
versus chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.
View Article : Google Scholar : PubMed/NCBI
|
